Comparative Pharmacology
Head-to-head clinical analysis: TOUJEO MAX SOLOSTAR versus TOUJEO SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOUJEO MAX SOLOSTAR versus TOUJEO SOLOSTAR.
TOUJEO MAX SOLOSTAR vs TOUJEO SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action. It binds to the insulin receptor, activating downstream signaling pathways to promote glucose uptake in peripheral tissues, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis.
Insulin glargine is a long-acting human insulin analog that binds to the insulin receptor, activating cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection once daily at the same time every day. Starting dose for patients with type 2 diabetes: 0.2 units/kg or 10 units once daily, titrated based on fasting plasma glucose. Maximum dose per injection: 160 units (2 mL) or 300 units (3 mL) depending on prefilled pen.
Subcutaneous injection once daily at the same time each day. Starting dose in insulin-naïve patients: 0.2 units/kg or 10 units once daily, titrated to achieve glycemic targets. Maximum single dose: 80 units per injection.
None Documented
None Documented
Terminal elimination half-life of 19 hours (range 16-21 h) in steady state, reflecting prolonged insulin glargine absorption from the subcutaneous depot.
Terminal half-life: 19 hours (range 14–24 hours) after subcutaneous administration due to slow absorption from injection site.
Degraded by insulin-degrading enzyme; minimal renal excretion (<1% unchanged). Biliary/fecal elimination accounts for the remainder.
Renal excretion of degradation products; minimal intact insulin in urine. Fecal elimination is negligible.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin